NewAmsterdam Pharma is a biopharmaceutical company that is focused on developing innovative therapies for patients with a variety of diseases. The company's lead product candidate, Firdapse® (amifampridine), is currently approved in the United States for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. The company is also developing Firdapse for the treatment of other rare neuromuscular diseases, such as congenital myasthenic syndromes (CMS) and anti-MuSK antibody positive myasthenia gravis (MuSK-MG).
In addition to Firdapse, NewAmsterdam Pharma has a pipeline of other product candidates in various stages of development. These include product candidates for the treatment of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and other rare diseases.
The company was founded in 2018 and is headquartered in Amsterdam, the Netherlands. Its mission is to develop innovative therapies that address unmet medical needs and improve the lives of patients around the world.
NewAmsterdam Pharma is a biopharmaceutical company that is focused on developing innovative therapies for patients with a variety of diseases. The company's lead product candidate, Firdapse® (amifampridine), is currently approved in the United States for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. The company is also developing Firdapse for the treatment of other rare neuromuscular diseases, such as congenital myasthenic syndromes (CMS) and anti-MuSK antibody positive myasthenia gravis (MuSK-MG).